INDY-AUTONOMOUS-CHALLENG
16.7.2024 16:01:31 CEST | Business Wire | Press release
On a busy Sunday afternoon, in front of a global audience of motorsport enthusiasts, The Indy Autonomous Challenge’s (IAC) self-driving AV-24 racecar set the record for the fastest autonomous Hillclimb at the Festival of Speed. The AV-24 is piloted by an AI Driver developed by Team PoliMOVE-MSU (Politecnico di Milano and Michigan State University).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716347266/en/
The IAC AV-24, a racecar driven by AI, sets autonomous record at the Goodwood Festival of Speed. (Photo: Business Wire)
The AV-24 performed a series of three runs during the iconic festival. The record was broken during their third and final run up the Goodwood Hill where the racecar reached a top speed of 111.2 mph (179 kph) and a finish time of 66.37 secs. The record-setting run can be watched here. The previous record has been held by Roborace since 2019 when their “DevBot 2.0” autonomous car clocked a 66.96 sec time at a top speed of 101.16 mph (162.8 kph).
Goodwood is known for its unforgiving narrow course, lined with hay bells and limited run-off space. Attempting an autonomous hill climb at the Festival of Speed required absolute control of grip and slippage from the AV-24’s Bridgestone racing tires as well as precision mapping and localization in a GPS limited environment resulting in a higher than usual reliance on the AV-24’s Luminar Iris lidars.
The IAC and PoliMOVE-MSU teams worked closely with Bridgestone’s tire engineers to optimize performance ahead of the Hillclimb including traveling to Bridgestone’s European Technical Center and European Proving Grounds in Rome. The team also had the unique chance to explore each step of tire production and test how impactful tire performance is on track.
Paul Mitchell, Chairman and President of the IAC: “For three years, the IAC has been pushing the boundaries of high-speed autonomy and setting new records along the way. The Goodwood Hillclimb is a historic backdrop with huge crowds and a global audience that is now aware of the potential of self-driving vehicles to be safely deployed on roads in the future.”
Professor Sergio Savaresi, PoliMOVE-MSU Team Principal: “This challenge represents an important milestone for autonomous mobility. This weekend we overcame significant challenges posed by a complicated track and temperamental weather patterns. Thanks to the exceptional work and skills implemented by our engineering team and tire performance ensured by our Bridgestone racing tires, we made history by showing the public that safe and high-speed vehicular autonomy is possible even in adverse conditions. Our record at the Goodwood Festival of Speed will inspire confidence in future autonomous driving applications.”
Sara Correa, Chief Marketing Officer for Bridgestone in the Americas, Europe, Middle East and Africa (EMEA) added, “Bridgestone is proud to support the PoliMOVE-MSU team in this incredible achievement at the Goodwood Festival of Speed 2024. We are committed to partnering with the IAC and its inspiring student engineers to continue testing and improving autonomous technologies in record-setting runs like this and beyond. Motorsports are part of Bridgestone’s DNA, always have been and always will be. And what really matters is that we take the learnings from experiences like this and apply them to the sustainable mobility solutions we develop for society and our customers.”
Visuals and footage including of the IAC’s Autonomous Hillclimb can be found here.
About the IAC: The Indy Autonomous Challenge (IAC) is a non-profit corporation based in Indianapolis, Indiana (USA) that organizes racing competitions among 10 university-affiliated teams representing 18 universities from around the world. Teams program AI drivers to pilot fully autonomous racecars and compete in a series of history-making events at iconic tracks. The IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in the safety and performance of autonomous vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, & YouTube.
About Bridgestone: Bridgestone is a global leader in tires and rubber building on its expertise to provide solutions for safe and sustainable mobility. Headquartered in Tokyo, the company employs approximately 130,000 people globally, conducting business in more than 150 countries and territories worldwide. Bridgestone offers a diverse product portfolio of premium tires and advanced solutions backed by innovative technologies, improving the way people around the world move, live, work and play.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716347266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom